Shennon Biotechnologies (ShennonBio), a trailblazing biotechnology firm focused on the development of precision immunotherapies for cancer, has announced a significant expansion of its executive leadership team and a successful $12 million financing round. The company has officially appointed veteran biotech executive Cyril Konto, M.D., as its new Chief Executive Officer, marking a pivotal transition as the firm prepares to advance its pipeline toward clinical trials.
The latest funding round was led by Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, and Saras Capital. This infusion of capital also saw continued commitment from existing investors, including DCVC, Foundation Capital, and AV8 Ventures. With this latest tranche, ShennonBio has now raised a total of $25 million to date to support its proprietary research and development efforts.
With the appointment of Dr. Konto, company founder Li Sun, Ph.D., will transition into the roles of President and Chief Technology Officer. In these positions, Dr. Sun will maintain a focus on the company’s long-term scientific strategy, the continued development of its integrated technology platform, and pipeline innovation.
“ShennonBio was founded to address fundamental challenges that have limited the development of precision immunotherapies, from identifying differentiated targets and highly functional therapeutic binders to predicting potential safety risks before candidates reach the clinic,” said Dr. Sun. “With $25 million raised to date, and Cyril joining as CEO, we are entering an important new stage for ShennonBio as we advance our first TCE (T-cell engager) programs toward the clinic.”
Dr. Konto arrives at ShennonBio with more than two decades of experience in oncology drug development, corporate strategy, and organizational growth. He most recently served as President and CEO of Ichnos Glenmark Innovation (IGI), where he was instrumental in reshaping the company’s portfolio to emphasize multispecifics in oncology. His impressive resume also includes high-level leadership roles at industry giants Allogene Therapeutics, Pfizer, and Bristol Myers Squibb, providing him with the deep clinical and strategic expertise necessary to lead a biotech startup through its next phase of development.
“ShennonBio has spent the last several years building a differentiated foundation spanning proprietary human data, target discovery, functional screening, therapeutic design and safety prediction,” Dr. Konto stated. “What attracted me to the Company is the opportunity to translate those capabilities into a new generation of precision immunotherapies. I look forward to working closely with Li and the team to advance our pipeline toward the clinic, establish strategic partnerships and build ShennonBio for its next stage of growth.”
As the company shifts its focus toward the clinic, the leadership transition and new capital signal a robust commitment to addressing the complexities of cancer treatment. ShennonBio’s integrated platform aims to streamline the development of safer, more effective immunotherapies, positioning the company as a key player to watch in the evolving landscape of oncology therapeutics.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
